13 Best Innovative Stocks to Buy According to Wall Street Analysts

Page 3 of 13

11. Beam Therapeutics Inc. (NASDAQ:BEAM)

Analyst Upside: 85.84%

Number of Hedge Fund Holders: 27

Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best innovative stocks to buy according to Wall Street analysts. H.C. Wainwright reiterated a Buy rating and $80 price target for Beam Therapeutics Inc. (NASDAQ:BEAM) on January 15, citing the company’s developments over its BEAM-302 therapy. This comes after Beam announced that it reached an agreement with the FDA on an expedited approval process for BEAM-302 in alpha-1 antitrypsin deficiency (AATD).

Beam Therapeutics Inc. (NASDAQ:BEAM) will take on about 50 more patients at the ideal biologic dose in its active Phase 1/2 trial in support of this filing. By the end of the first quarter of 2026, the company anticipates reporting new data and outlining the next phases for important development.

Beam Therapeutics Inc. (NASDAQ:BEAM) wrapped up 2025 with approximately $1.25 billion in cash, cash equivalents, and convertible securities, expanding its anticipated financial runway beyond 2029. This budget provides funds to carry out critical development of BEAM-302 and the planned risto-cel launch as the company moves into the commercial phase.

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company developing precision genetic medicines using its proprietary base-editing technology. Its main products include investigational therapies such as BEAM-101 and BEAM-302.

Page 3 of 13